Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford scientists are celebrating after being given a £2m boost for medical research.

Two teams of Oxford University researchers were awarded a total of £1.3m, while Oxford University spin-out company Brainomix, which develops medical imaging software for the treatment of stroke, received £663,000.

Dr Trevor Yeung of the Nuffield Department of Surgical Sciences and his team, which includes Dr Elizabeth Bird-Lieberman of Oxford University Hospitals Trust, was awarded £634,000. Their work, which involves a fluorescent dye being sprayed on to the lining of the bowel, could help doctors distinguish between normal and cancerous tissues.

Dr Bird-Lieberman commented: 'We are delighted to receive this prestigious funding as we feel this work has potential to improve care for colon cancer. We feel that the best way to decrease cancer rates and improve outcome is by early detection and this work has the potential to do this for colon cancer.'

Researchers at the Jenner Institute working on a universal flu vaccine were awarded almost £700,000. Lead scientist Professor Sarah Gilbert said: ‘We are very pleased because it’s the next step in a programme we have been working on for a while.’

The funding comes from the Biomedical Catalyst, a joint programme run by the Medical Research Council and Innovate UK.

Similar stories

ASPI honours ProtecT Trial for pioneering research demonstrating the safety of active surveillance

The ProtecT Trial has been named the 2024 recipient of the Active Surveillance Patients International (ASPI) Special Award for game-changing research in the development of the Active Surveillance approach to managing low-risk prostate cancer.